dimethyl fumarate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 27 Diseases   27 Trials   27 Trials   3795 News 


«12...1819202122232425262728...4546»
  • ||||||||||  dimethyl fumarate / Generic mfg.
    [VIRTUAL] Quantitative spinal cord MRI as a biomarker of treatment response to dimethyl fumarate in MS (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_602;    
    There were no significant changes in quantitative SC-MRI measures in pwMS on DMF, similar to what was observed in HCs. Our findings suggest that treatment with DMF prevents MS-related microstructural change in the SC over two years, promoting the utility of quantitative SC-MRI as a biomarker of treatment response in MS.
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
    [VIRTUAL] Evaluating DMT escalation based on isolated MRI activity (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_570;    
    Methods : From the Vienna Innsbruck MS database (VIMSD), we included RMS patients (18-65 years) with a) newly initiated moderately effective DMT (interferon-beta, glatiramer acetate, dimethyl fumarate, or teriflunomide) continued for 12 months, b) clinical stability (no relapses or disability progression) on DMT for 12 months, c) MRI at baseline (MRI-0) and after 12 months of DMT (MRI-1), and d) available clinical follow-up for ≥3 years... In our real-world cohort of clinically stable patients, DMT escalation based on isolated MRI activity only changed outcome when MRI activity fulfilled at least MAGNIMS criteria (exceeding 3 new/enlarged T2 lesions).
  • ||||||||||  dimethyl fumarate / Generic mfg.
    [VIRTUAL] Impact of an educational program on the DMF persistence in real-life: TECFIRELIFE study (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_532;    
    In our real-world cohort of clinically stable patients, DMT escalation based on isolated MRI activity only changed outcome when MRI activity fulfilled at least MAGNIMS criteria (exceeding 3 new/enlarged T2 lesions). Objectives: The aim of the TECFIRLIFE study (TECFIder
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
    [VIRTUAL] Treatment patterns in patients with multiple sclerosis: a single hospital cohort study in Sweden (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_528;    
    Most patients were treated with a DMT within months of diagnosis, with predominant initial use of interferons, and switching to more potent agents in later lines of therapy. Prescribing patterns are changing and expected to evolve further with earlier use of powerful agents.
  • ||||||||||  dimethyl fumarate / Generic mfg., fingolimod / Generic mfg.
    [VIRTUAL] Persistent lymphopenia after dimethyl fumarate and fingolimod treatment (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_490;    
    It is possible that an accumulate effect of a long period treatment with natalizumab, partly prevent entry of antigen-presenting cells such as dendritic and macrophages into the muscle and therefore the immune response to vaccine is slightly reduced. ALC recovery after DMF or fingolimod withdrawal is usually rapid, nevertheless it may require longer time in some patients what potentially leading to delayed initiation of a new MS therapy.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] COVID-19 in a neuroimmunology and multiple sclerosis referral unit (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_336;    
    Los datos de nuestra serie estan en concordancia con otros estudios, mostrando que la esclerosis múltiple per se y los diferentes tratamientos immunomoduladors no son un factor de riesgo para el COVID19. Es importante acelerar la vacunación de los pacientes con esclerosis múltiple para reducir la posibilidad de infección por SARS-CoV-2.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    [VIRTUAL] CSF inflammatory markers: prediction of treatment response in early relapsing remitting multiple sclerosis? (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_257;    
    The CSF inflammatory profile may provide additional prognostic information to both clinical and MRI variables, and is a possible candidate in predicting response to the first-line treatment. The association between the lymphoid chemokine CXCL13 and both disease activity and cortical pathology and its prognostic value has been confirmed in a homogenous cohort.
  • ||||||||||  Mayzent (siponimod) / Novartis
    [VIRTUAL] Assessing the immune response to SARS-CoV-2 mRNA vaccines in patients with secondary progressive multiple sclerosis treated with siponimod (AMA-VACC clinical trial) (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_256;    
    Cohort 1 receives SARS-CoV-2 mRNA vaccination while continuing their current siponimod treatment, cohort 2 interrupts siponimod treatment for for the purpose of a full vaccination cycle and cohort 3 receives vaccination during continuous treatment with first-line DMTs (dimethylfumarate, glatirameracetate, interferons, teriflunomide) or no current treatment in clinical routine... This analysis will provide first data on the immune response after SARS-CoV-2 mRNA vaccination in patients with SPMS treated with siponimod and enable physicians to make an informed decision on the coordination of SARS-CoV-2 mRNA vaccination and SPMS treatment.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    [VIRTUAL] Assessing treatment response to oral drugs for multiple sclerosis in real world setting: a MAGNIMS study (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_243;    
    We retrospectively collected data of RRMS patients who started fingolimod (FNG), teriflunomide (TNF) or dimethyl fumarate (DMF) according to the following criteria: treatment-naive or switching from injectable DMTs; at least 1 year treatment duration; brain MRI scan collected at baseline and year 1; at least 3 years of clinical follow-up... We extend the results of previous studies, by demonstrating that early relapses and MRI activity in the first year of treatment are associated with an increased risk of short-term confirmed disability worsening and relapses in patients treated with oral DMTs.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie
    [VIRTUAL] ECTRIMS Lecture: Gains by translation: from basic neuroimmunology to disease modifying therapies (Stream 1 Clinical) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_111;    
    In the 1990ies the first two treatments, interferon-beta and glatiramer-acetate, which were based on the above data, became available, and a decade later, the anti-VLA4 antibody natalizumab, which is highly effective in MS, was approved...During the last ten years several small molecules like cladribine, teriflunomide, dimethylfumarate, and several S1P receptor modulators (fingolimod, ozanimod, siponimod), and also biologics including an antibody against the lymphocyte surface marker CD52 (alemtuzumab), another against the IL-2 receptor alpha chain, (daclizumab; withdrawn) and particularly the anti-CD20 antibodies (ocrelizumab, ofatumumab), which efficiently deplete B cells and are highly effective in MS, have been approved...We will soon probably not only see the advent of therapies targeting B cell function more specifically, but hopefully also antigen-specific, neuroprotective and remyelinating therapies. The lecture will focus on particularly instructive examples of translational research.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Underutilization of Contraception in Young Females with Demyelinating Disorders. (Pubmed Central) -  Jul 9, 2021   
    In participants with MS from the NARCOMS registry, there was no significant difference in confirmed disability (PDDS) worsening over 5 years between those treated with DMF versus FTY. Contraceptive use in young females with demyelinating disorders is less than 1/3rd of the general population with particular discrepancies in persons of Hispanic/Latino descent.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia. (Pubmed Central) -  Jul 9, 2021   
    A consensus also supported continuing treatment regimens with fingolimod (or siponimod) and cladribine tablets for a patient without active Covid-19...Where treatment is already ongoing, vaccination against Covid-19 should be administered immediately without disruption of treatment (first-line DMTs, natalizumab, fingolimod), when lymphocytes have recovered sufficiently (cladribine tablets, alemtuzumab) or 4 months after the last dose (ocrelizumab). These recommendations will need to be refined and updated as new clinical evidence in this area emerges.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Clinical, Retrospective data, Journal:  Multiple sclerosis hospitalizations among users of oral disease-modifying therapies. (Pubmed Central) -  Jul 8, 2021   
    These recommendations will need to be refined and updated as new clinical evidence in this area emerges. Oral disease-modifying therapies are comparably effective for the outcome of multiple sclerosis hospitalization, even in older adults.
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    Clinical, Journal, Real-world evidence:  Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. (Pubmed Central) -  Jul 1, 2021   
    There was no significant difference between treatment groups in discontinuation rate due to side effects, although more patients reported side effects when treated with dimethyl fumarate. Our findings suggests that dimethyl fumarate has a lower risk of discontinuation because of treatment failure among both treatment-experienced and treatment-naive patients.